Skip to main content
Premium Trial:

Request an Annual Quote

EPO Issues Notice of Intent to Grant Alnylam Patent Covering siRNA Modifications

Premium

Alnylam Pharmaceuticals said this week that the European Patent Office has issued the company a notification of its intent to grant the company a patent covering "compositions and methods … for chemically modified siRNAs containing phosphorothioate and 2-O-alkyl modifications without any siRNA length restrictions."

The patent application, No. 04 718 537, is entitled, "Therapeutic Compositions," and claims chemical modifications "broadly used to achieve potency, stability, and selectivity of siRNAs; features that are needed to design siRNAs with drug-like properties for therapeutic applications," the company noted.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.